SCHEMBL1635181

SCHEMBL1635181

COc1ccc(NS(=O)(=O)CC(=O)O)cc1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
LMNA P02545 3/20 0.41
HTT P42858 3/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
SHMT2 P34897 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
DRD2 P14416 1/20 0.39
IMPDH2 P12268 1/20 0.39
IMPDH1 P20839 1/20 0.39
FABP4 P15090 2/20 0.39
LY6K Q17RY6 1/20 0.38
WDR5 P61964 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1635334 0.80 NPSR1 (0.50) SMN1; SMN2LMNAMAPK1MEN1KMT2A
SCHEMBL1636738 0.80 L3MBTL1 (0.39) SMN1; SMN2LMNAHTTALOX15MAPK1
SCHEMBL831093 0.79 GAA (0.51) SMN1; SMN2LMNAHTTALOX15MAPK1
SCHEMBL1634365 0.78 DRD2 (0.47) SMN1; SMN2LMNAHTTMAPK1DRD2
SCHEMBL2244136 0.76 CA1 (0.47) SMN1; SMN2LMNAHTTALOX15MAPK1
SCHEMBL1636450 0.76 L3MBTL1 (0.43) SMN1; SMN2LMNAHTTALOX15MAPK1
SCHEMBL1122405 0.76 LMNA (0.48) LMNAHTTMAPK1MEN1KMT2A
SCHEMBL28813545 0.75 SMN1; SMN2 (0.52) SMN1; SMN2LMNAHTTALOX15MAPK1
SCHEMBL14799054 0.74 SMN1; SMN2 (0.55) SMN1; SMN2LMNAHTTALOX15MAPK1
SCHEMBL7532262 0.74 DRD2 (0.58) SMN1; SMN2LMNAHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3138832-A1 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS Temple University - Of The Commonwealth System of Higher Education (US) 2017-03-08 EP disclosed
US-7932242-B2 Anticancer agents; radiation and chemical resistance TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-04-26 US disclosed
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-03-06 US disclosed
EP-1740530-A4 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS UNIV TEMPLE (US) 2008-02-27 EP disclosed
EP-1740530-A2 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS Temple University of the Commonwealth System of Higher Education (US) 2007-01-10 EP disclosed
WO-2005089269-A2 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders PCNA, MKI67, TP53 SMN1; SMN2 2736/4885LMNA 2048/4885HTT 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.